Compare · NVST vs WST
NVST vs WST
Side-by-side comparison of Envista Holdings Corporation (NVST) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVST and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $24.52B, about 5.6x NVST ($4.41B).
- Over the past year, NVST is up 30.0% and WST is up 42.5% - WST leads by 12.5 points.
- NVST has been more active in the news (9 items in the past 4 weeks vs 1 for WST).
- NVST has more recent analyst coverage (24 ratings vs 18 for WST).
- Company
- Envista Holdings Corporation
- West Pharmaceutical Services Inc.
- Price
- $27.47+0.44%
- $348.50-1.36%
- Market cap
- $4.41B
- $24.52B
- 1M return
- +3.15%
- +5.23%
- 1Y return
- +29.97%
- +42.52%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2019
- News (4w)
- 9
- 1
- Recent ratings
- 24
- 18
Envista Holdings Corporation
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands. This segment also offers software packages used for the treatment planning of dental implants and prosthetics. The company's Equipment & Consumables segment develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements, and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, KaVo, Kerr, Metrex, Sybron Endo, Total Care, and Pentron brands to dental offices, clinics, and hospitals. The company was incorporated in 2018 and is headquartered in Brea, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest NVST
- SVP, Strategy & Bus. Dev. Reis Mischa sold $220,000 worth of shares (8,000 units at $27.50) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 27,321 units (SEC Form 4)
- Chief Executive Officer Keel Paul A was granted 179,730 shares, increasing direct ownership by 48% to 551,304 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Hammes Eric D.
- Envista Holdings Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- New insider Thomas Coree K. claimed ownership of 19,069 shares (SEC Form 3)
- Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
- SEC Form 10-Q filed by Envista Holdings Corporation
- Envista Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Envista Reports Second Quarter 2026 Results
- Envista to Host Investor Day on September 17, 2026
Latest WST
- SVP & Chief Financial Officer Mcmahon Robert W. converted options into 7,149 shares and covered exercise/tax liability with 3,109 shares, increasing direct ownership by 136% to 7,021 units (SEC Form 4)
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target